- The round saw participation from Anthill Ventures.
- The investment will enable Cureous Labs to manufacture its first batch of devices, build inventory, and expand its team with key hires in sales and business development. It will also fund the launch of the company’s first Disinfection Centre, facilitate product safety testing and certifications, and accelerate the expansion of its product portfolio for existing B2B customers.
- Cureous Labs has earned prestigious recognition through grants and awards from BIRAC, MeitY, the Bill & Melinda Gates Foundation, is a Swissnex AIT Awardee, and has been supported by Social Alpha and the SBI Foundation for its impactful healthcare innovations.
- So far, Inflection Point Ventures has invested over INR 800 Cr across 220+ startups.
Bangalore,August 13, 2025 – Cureous Labs, an innovative medical technology startup focused on improving patient care and nursing efficiency, has raised ₹1.66 crore in a Seed funding round led by Inflection Point Ventures (IPV), with participation from Anthill Ventures.
The funding will be used to manufacture the first batch of Cureous’ flagship automated patient repositioning systems (Eturnal™), build inventory, and scale commercial operations through strategic hiring in sales and business development. It will also support the launch of the company’s first disinfection Centre, enable product safety testing and certifications, and expand the product portfolio for B2B customers across India.
Asish Mohandas, Founder & CEO of Cureous Labs, is a Biodesign Fellow from the prestigious School of International Biodesign at AIIMS & IIT Delhi and holds a Master of Design from IIT Kanpur. He is also the first National James Dyson Awardee for a medical device developed during his time at IIT Kanpur. With a strong foundation in healthcare innovation and user-centered design, Asish brings deep expertise in creating impactful medical technologies tailored to the Indian healthcare landscape.
Vinay Bansal, Founder, IPV says, “What drew us to invest in Cureous Labs is their commitment to the ‘Prevention is better than Cure’ idea. Around the world there are several bedridden patients suffering from pressure injuries, adding to the already existing ailments. Additionally, it also puts strain on the caregivers making it tedious and risky for them to care for the patients. Cureous Labs has used technology to ease the burden of care while making pressure injury prevention more affordable and accessible to organizations across the globe.”
Cureous Labs has developed India’s first retrofittable automatic patient repositioning system with advanced pressure relief, designed to help prevent bedsores and reduce caregiver injuries. Being priced at just 1/5th the cost of international alternatives, the solution becomes both accessible as well as cost-effective. The solution is built on more than 2 years of intensive clinical research and insight from across 100+ Hospitals in India and Australia.
Cureous Labs’ devices are deployed across hospitals, rehabilitation centers, and home care settings which showcases its real-world usage. With over 30,000 hours of usage and more than 14,000 automated patient turns, this technology has proven its credibility and impact. The startup is currently running an active B2B and B2C sales and rental pilots across South India.
Asish Mohandas, the founder and CEO of Cureous Labs added: “At Cureous, our mission is to create technologies that empower independent living. Eturnal™, our one-of-a-kind automated patient turning solution, helps prevent pressure injuries while reducing caregiver dependency and effort. We aim to build a portfolio of solutions for geriatric and long-term care. IPV’s early belief in our vision gives us the confidence and resources to scale Cureous into a category-defining company in this space.”
The global market for pressure injury prevention and patient care is substantial, with over 1.1 billion people aged above 60 and 140 million over the age of 80, highlighting the growing need for elderly care solutions. An estimated 154 million people worldwide are bedridden and at risk of developing pressure injuries, contributing to a global market size of $277 billion. In India, the Total Addressable Market (TAM) stands at $8.34 billion, with a Serviceable Available Market (SAM) of $1.56 billion and a Serviceable Obtainable Market (SOM) of $656 million, indicating strong potential for scalable impact and growth.
About Cureous Labs:
Cureous Labs is a MedTech spinoff from the prestigious Biodesign Fellowship at AIIMS & IIT Delhi, dedicated to developing intelligent, automated solutions for pressure injury prevention. Its flagship product Eturnal™ offers a first-of-its-kind repositioning system that minimizes caregiver effort while enhancing patient comfort and safety. Designed to seamlessly fit into homes, hospitals, and senior care facilities, Cureous is redefining standards in long-term and critical care support.
About Inflection Point Ventures and Physis Capital:
Inflection Point Ventures (IPV) is an angel investing platform with over 24,000+ CXOs, HNIs, and Professionals to together invest in startups. The firm supports new-age entrepreneurs by providing them with monetary & experiential capital and connecting them with a diverse group of investors. IPV has launched a $50 Mn CAT 2 VC fund, Physis Capital, to invest in Pre-Series A to Series B growth-stage start-ups. The fund has already deployed capital in six startups so far, with a few deals in advanced stages of pipeline.
